Sagimet Biosciences Announces First Patient Dosed in AURORA Phase 3 U.S. Clinical Trial of Denifanstat for Moderate to Severe Acne
Sagimet expects topline results in the second half of 2027, with AURORA intended to support a potential U.S. approval application.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Sagimet Biosciences (Nasdaq: SGMT) has dosed the first patient in AURORA, its U.S. Phase 3 trial of denifanstat for moderate to severe acne. The randomized, double-blind, placebo-controlled trial will evaluate the efficacy and safety of 50 mg once daily. It is designed to enroll approximately 800 U.S. patients aged 12 and older, including an expected 450 adolescents aged 12 to 17.
AURORA includes a 12-week blinded treatment period followed by a 40-week extension in which eligible patients receive treatment openly. Sagimet expects topline results in the second half of 2027; the trial is intended to support a potential U.S. New Drug Application submission. Denifanstat inhibits fatty acid synthase, an enzyme involved in fat production. Ascletis holds an exclusive license in China, while Sagimet is developing denifanstat in the rest of the world.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointFirst patient dosed advances denifanstat’s U.S. Phase 3 program toward a potential approval application.
- Minor point. Forward-looking: it has not happened yet and may not happen.Topline results are expected by Sagimet in the second half of 2027.
Negative
- None.
Key Figures
- Planned enrollment
- Approximately 800 U.S. patients
- AURORA Phase 3 trial
- Adolescent enrollment
- 450 patients aged 12 to 17 years
- Expected subset of AURORA enrollment
- Denifanstat dose
- 50 mg once daily
- AURORA Phase 3 trial
- Double-blind treatment period
- 12 weeks
- AURORA trial design
- Open-label extension
- 40 weeks
- For eligible AURORA patients
- Expected topline results
- Second half of 2027
- AURORA Phase 3 trial
Previous Clinical trial Reports
-
Ascletis reported 52-week extension outcomes for denifanstat in China.
-
AURORA sites were identified and screening was planned ahead of U.S. enrollment.
-
FDA cleared denifanstat's IND and issued a Study May Proceed letter.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
fasn medical
new drug application (nda) regulatory
double-blind medical
placebo-controlled medical
open-label extension medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- With first patient dosed in AURORA Phase 3 clinical trial, Sagimet advances denifanstat's U.S. registrational program, building on positive Phase 3 clinical results in China from license partner Ascletis
- Pivotal trial designed to enroll approximately 800 U.S. patients, including 450 adolescents aged 12 and older
- If approved, denifanstat has the potential to address a significant unmet need among approximately 10 million Americans with moderate to severe acne
FOSTER CITY, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing inhibitors of fatty acid synthase (FASN), a key lipid synthesis regulator, for acne, today announced that the first patient has been dosed in AURORA, its pivotal U.S. Phase 3 clinical trial of denifanstat in adults and adolescents aged 12 years and older with moderate to severe acne. AURORA is intended to support a potential U.S. New Drug Application (NDA) submission. The trial builds on positive Phase 3 clinical results and subsequent 52-week open-label extension data generated by Sagimet’s license partner Ascletis BioScience Co. Ltd. (Ascletis) in China. Denifanstat is a once-daily oral small molecule fatty acid synthase (FASN) inhibitor being developed by Ascletis as ASC40 in China where it holds an exclusive license to denifanstat, and by Sagimet in the rest of the world.
“Dosing the first patient in our AURORA Phase 3 clinical trial marks a significant milestone for Sagimet,” said David Happel, Chief Executive Officer of Sagimet. “Our focus is on advancing this registrational trial, with topline results expected in the second half of 2027. If approved, denifanstat would be the first once-daily oral acne treatment with a novel mechanism of action approved by the FDA for the treatment of acne in more than 40 years, offering a new treatment option for the approximately 10 million U.S. patients living with moderate to severe acne.”
AURORA is a multicenter, randomized, double-blind, placebo-controlled registrational Phase 3 clinical trial designed to evaluate the efficacy and safety of denifanstat 50 mg once daily in approximately 800 U.S. patients aged 12 years and older, of which 450 are expected to be adolescents aged 12 to 17 years. The trial includes a 12-week double-blind treatment period followed by a 40-week open-label extension for eligible patients.
“As well as the positive Phase 3 data generated by our license partner Ascletis, Sagimet’s mechanistic non-clinical and clinical data provide further support for denifanstat’s differentiated approach to targeting sebum production and inflammation, key drivers of acne,” said Andreas Grauer, MD, Chief Medical Officer of Sagimet. “We look forward to conducting our registrational Phase 3 clinical trial and bringing denifanstat to patients and their families who we feel are currently underserved by the available treatment options.”
The 52-week results from Ascletis' Phase 3 open-label extension clinical trial were recently presented as posters at the European Academy for Dermatology and Venerology (EADV) Congress 2026 and the 2026 Fall Clinical Dermatology Conference. The posters are available in the Science section of Sagimet’s website (here).
About the AURORA Phase 3 Clinical Trial
AURORA (NCT07863193) is a multi-center, randomized, double-blind, placebo-controlled Phase 3 clinical trial of denifanstat in moderate to severe acne. AURORA is anticipated to enroll approximately 800 U.S. patients aged 12 years and older, of which 450 are expected to be adolescents aged 12 to 17 years. Patients will be randomized 2:1 to receive denifanstat 50 mg or placebo once daily for 12 weeks. The trial will have three co-primary endpoints that will be assessed at week 12: the proportion of patients achieving treatment success in a global assessment score, defined as at least a 2-point reduction from baseline with a score of 0 (clear) or 1 (almost clear); absolute change in inflammatory skin lesion counts from baseline; and absolute change in non-inflammatory skin lesion counts from baseline. A subset of approximately 530 patients completing the double-blind period will be eligible to enter a 40-week open-label extension evaluating the long-term safety of denifanstat.
About Denifanstat
Denifanstat is an oral, once-daily FASN inhibitor in development for the treatment of moderate to severe acne. In trials conducted by Sagimet’s license partner, Ascletis BioScience Co. Ltd. (Ascletis) in China, denifanstat met all primary and secondary endpoints in a 12-week randomized, double-blind Phase 3 clinical trial in moderate to severe acne vulgaris and was generally well-tolerated and showed improvements in all efficacy endpoints measured at 52 weeks (secondary endpoints of the trial) in an open-label extension clinical trial evaluating denifanstat’s long-term safety. Denifanstat is being developed by Ascletis as ASC40 for acne in China and by Sagimet in the rest of world.
About Acne
Acne is one of the most common skin conditions in the U.S., with approximately 50 million Americans affected annually and more than 5 million seeking medical treatment for acne each year. Acne affects around
About Sagimet Biosciences
Sagimet is a clinical-stage biopharmaceutical company advancing a portfolio of novel fatty acid synthase (FASN) inhibitors. FASN is a key regulator of the de novo lipogenesis pathway, which is overactive in acne and can cause elevated sebum and inflammation. FASN is also implicated in other diseases, including MASH and certain FASN-dependent tumor types. Denifanstat, Sagimet’s lead drug candidate, is an oral, once-daily FASN inhibitor currently being evaluated in a U.S. Phase 3 registrational clinical trial for moderate to severe acne. For more information, visit www.sagimet.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding the expected timing of the presentation of data from ongoing clinical trials, Sagimet’s clinical development plans and related timelines and anticipated development milestones, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause Sagimet’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, these statements can be identified by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this press release are only predictions. Sagimet has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that Sagimet believes may affect its business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Sagimet’s control, including, among others: the clinical development and therapeutic potential of denifanstat, TVB-3567 or any other drug candidates or combination therapies developed by Sagimet; Sagimet’s ability to advance drug candidates into and successfully complete clinical trials within anticipated timelines; Sagimet’s relationship with Ascletis, and the success of its development and registration efforts for denifanstat; the accuracy of Sagimet’s estimates regarding its capital requirements and Sagimet’s ability to maintain and successfully enforce adequate intellectual property protection. These and other risks and uncertainties are described more fully in the “Risk Factors” section of Sagimet’s most recent filings with the Securities and Exchange Commission and available at www.sec.gov. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in these forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, Sagimet operates in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that Sagimet may face. Except as required by applicable law, Sagimet does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Investor Contact:
Joyce Allaire
LifeSci Advisors
JAllaire@LifeSciAdvisors.com
Media Contact:
Maggie Whitney
LifeSci Communications
mwhitney@lifescicomms.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What is Sagimet’s AURORA Phase 3 acne trial evaluating?
AURORA evaluates the efficacy and safety of denifanstat 50 mg once daily against placebo in moderate to severe acne. The trial is designed to enroll approximately 800 U.S. patients aged 12 and older, including an expected 450 adolescents aged 12 to 17.
When does Sagimet expect results from the AURORA denifanstat trial?
Sagimet expects topline results in the second half of 2027. AURORA is intended to support a potential U.S. New Drug Application submission.